Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $550
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $500 to $550.
August 05, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Vertex Pharmaceuticals and raises the price target from $500 to $550.
The raised price target and maintained Outperform rating from a reputable analyst like Hartaj Singh at Oppenheimer is likely to positively impact Vertex Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100